What is Natera's stock symbol?
Mar 09, 2022 · Exhibits, archives showcase community's history. Shares of Natera (NASDAQ: NTRA) are in free fall this morning, down more than 35%, after Hindenburg Research released a short report on the company ...
Is Natera a buy or sell on price targets?
Apr 22, 2022 · Natera Loses False Advertising Trial; Natera Stock Drops Significantly on Short Seller Report - Securities Investigation on Behalf of Natera Shareholders - Benzinga benzinga.com - March 15 at 4:35 PM: CareDx wins $45 mln verdict against Natera for false advertising - Reuters reuters.com - March 15 at 4:35 PM (NTRA) News: Why did Natera Stock Drop?
Why is NTRA stock down 50% today?
Apr 07, 2022 · Natera's stock was trading at $31.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NTRA stock has increased by 2.1% and is now trading at $31.67.
When did Natera go public?
Natera to pay executive salaries in stock the rest of 2022, citing 'confidence' in outlook despite sharp stock selloff. Natera Inc. said it has changed its executive and director pay packages so ...
See more
Mar 18, 2022 · That's what has happened to genetic testing company Natera (NTRA-17.43%), which has fallen after a report criticizing its business made investors think twice about the stock.
Is Natera a good investment?
Is Natera a publicly traded company?
Is Natera overvalued?
When did Natera go public?
What is NIPT?
Is Natera a buy right now?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 1...
How has Natera's stock been impacted by Coronavirus?
Natera's stock was trading at $31.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since...
When is Natera's next earnings date?
Natera is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Natera .
How were Natera's earnings last quarter?
Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, February, 24th. The medical research company reported ($1.48) earnings per s...
What guidance has Natera issued on next quarter's earnings?
Natera updated its FY 2022 earnings guidance on Thursday, March, 17th. The company provided earnings per share guidance of for the period. The comp...
What price target have analysts set for NTRA?
11 equities research analysts have issued 1 year target prices for Natera's shares. Their forecasts range from $80.00 to $160.00. On average, they...
Who are Natera's key executives?
Natera's management team includes the following people: Stephen Chapman , President, Chief Executive Officer & Director Robert A. Schueren , Chi...
What is Steve Chapman's approval rating as Natera's CEO?
158 employees have rated Natera CEO Steve Chapman on Glassdoor.com . Steve Chapman has an approval rating of 91% among Natera's employees. This pu...
Who are some of Natera's key competitors?
Some companies that are related to Natera include Exact Sciences (EXAS) , Guardant Health (GH) , Elekta AB (publ) (EKTAY) , CareDx (CDNA) , Ve...
Natera Media Sentiment
Media Coverage
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Natera (NASDAQ NTRA) News Headlines Today
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Is Natera a buy right now?
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
What stocks does MarketBeat like better than Natera?
12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock.
When is Natera's next earnings date?
Wall Street analysts have given Natera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Natera wasn't one of them.
How were Natera's earnings last quarter?
Natera is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Natera.
How has Natera's stock been impacted by COVID-19 (Coronavirus)?
Natera, Inc. (NASDAQ:NTRA) issued its earnings results on Thursday, August, 5th. The medical research company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.27.
What guidance has Natera issued on next quarter's earnings?
Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NTRA shares have increased by 287.3% and is now trading at $120.15.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for NTRA?
Natera updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600 million-$620 million, compared to the consensus revenue estimate of $567.64 million.
New Strong Sell Stocks for August 10th
12 Wall Street analysts have issued 12 month price objectives for Natera's stock. Their forecasts range from $90.00 to $160.00. On average, they expect Natera's stock price to reach $138.27 in the next year.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021
Earnings Preview: Natera (NTRA) Q2 Earnings Expected to Decline
Natera (NTRA) delivered earnings and revenue surprises of -25.71% and 1.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
This Explosive Biotech Is Taking On a Huge New Market
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Was The Smart Money Right About Piling Into Natera Inc (NTRA)?
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists.
Earnings Preview: Natera (NTRA) Q1 Earnings Expected to Decline
Natera (NTRA) delivered earnings and revenue surprises of 29.52% and 31.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Natera a lawsuit?
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What is a NATERA?
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal's™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
When is the 2021 ATC?
(NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ability of its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera, to predict outcomes with immunotherapy in a randomized clinical trial. The study, which can be found here, is Signatera's 12th peer-reviewed publication and is the first publication that shows the predictive capabilities of a molecular residual disea
